

AD-A262 108



FIC

ECTE

MAR 12 1993

12

**CHEMICAL
RESEARCH,
DEVELOPMENT &
ENGINEERING
CENTER**

CRDEC-TR-398


**COMPUTER-ASSISTED DETERMINATION
OF MINIMUM ENERGY CONFORMATIONS
VI. A PHARMACOPHORE MODEL OF THE ACTIVE REGION
OF THE ALPHA2-ADRENOCEPTOR**

**William P. Ashman
Alexander P. Mickiewicz
Todd M. Nelson**

RESEARCH DIRECTORATE

September 1992

Approved for public release; distribution is unlimited.



**U.S. ARMY
ARMAMENT
MUNITIONS
CHEMICAL COMMAND**

Aberdeen Proving Ground, Maryland 21010-5423

88 3 11 066

93-05236



Disclaimer

The findings in this report are not be construed as an official Department of the Army position unless so designated by other authorizing documents.

DTIC QUALITY INSPECTED 1

Accession For	
NTIS CRA&I	☒
DTIC TAB	☒
Unannounced	☒
Justification _____	
By _____	
Distribution /	
Availability Codes	
Dist	Avail and/or Special
A-1	

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.				
1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE 1992 September	3. REPORT TYPE AND DATES COVERED Final, 88 Jun - 91 Sep	
4. TITLE AND SUBTITLE Computer-Assisted Determination of Minimum Energy Conformations, VI. A Pharmacophore Model of the Active Region of the Alpha2-Adrenoceptor			5. FUNDING NUMBERS PR-1C162622A554 1C161102A71A	
6. AUTHOR(S) Ashman, William P.; Mickiewicz, Alexander P.; and Nelson, Todd M.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) CDR, CRDEC, ATTN: SMCCR-RSP-C, APG, MD 21010-5423			8. PERFORMING ORGANIZATION REPORT NUMBER CRDEC-TR-398	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)			10. SPONSORING/MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release; distribution is unlimited.			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words) Molecular modeling and computational chemistry techniques are used to analyze compounds in developing pharmacophores of biological receptors to use as templates in structure activity relationship studies and to design new chemicals having physiological activity of interest. In this study, the results of x-ray crystal analyses and PM3 semi-empirical molecular orbital conformational analyses are used to determine the three-dimensional representations of selected adrenergic compounds known to be agonists with the alpha2-adrenoceptor in achieving optimized geometries and electrostatic parameters. The alpha2-adrenergic agonists interact with the adrenergic system receptors to produce various increases or decreases in hemodynamic responses (i.e., hypertension, hypotension, bradycardia) and sedation. A pharmacophore model of the active region of the alpha2-adrenoceptor is described based on the superimposition of common structural, electrostatic, and physicochemical features of the compounds. Using the model to predict compound adrenergic activity and to design alpha2-adrenergic compounds is discussed.				
14. SUBJECT TERMS Molecular modeling Pharmacophore Alpha2-adrenergic compounds			15. NUMBER OF PAGES 44	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT UNCLASSIFIED	18. SECURITY CLASSIFICATION OF THIS PAGE UNCLASSIFIED	19. SECURITY CLASSIFICATION OF ABSTRACT UNCLASSIFIED	20. LIMITATION OF ABSTRACT UL	

Blank

PREFACE

The work described in this report was authorized under Project Nos. 1C162622A554, Chemical Munitions, and 1C161102A71A, Research in CW/CB Defense. This work was started in June 1988 and completed in September 1991.

The use of trade names or manufacturers' names in this report does not constitute an official endorsement of any commercial products. This report may not be cited for purposes of advertisement.

Reproduction of this document in whole or in part is prohibited except with permission of the Commander, U.S. Army Chemical Research, Development and Engineering Center (CRDEC), ATTN: SMCCR-SPS-T, Aberdeen Proving Ground, MD 21010-5423. However, the Defense Technical Information Center and the National Technical Information Service are authorized to reproduce the document for U.S. Government purposes.

This report has been approved for release to the public.

Acknowledgments

The authors wish to thank Byron Bloor, University of California, Los Angeles, CA, for his helpful discussions on the adrenergic system; Fu-Lian Hsu, Research Directorate, CRDEC, for his advice on synthesis and chemical interactions; Duane Miller and Yoshiya Amomiya, Ohio State University, Columbus, OH, for their assistance in the synthesis of suggested alpha2-adrenergic compounds; Christopher Cramer, Research Directorate, CRDEC, for his helpful discussions on quantum chemistry and the use of MOPAC; and Brian Meehan, a summer student apprentice, CRDEC, for his technical assistance and work on the report figures.

Blank

CONTENTS

	Page
1. INTRODUCTION	7
2. EXPERIMENTATION	7
2.1 Compound Structures	7
2.2 Three-Dimensional Minimum Energy Conformation Optimization	7
2.3 Alpha2-Adrenoceptor Pharmacophore Development	9
3. RESULTS	10
3.1 Three-Dimensional Conformations of Selected Alpha2- Adrenergic Compounds	10
3.2 Alpha2-Adrenoceptor Pharmacophore Model (A2ARPhar) .	10
3.3 Intra-Atomic Distances and Angles	13
3.4 Agonist-A2ARPhar Interaction Distance Measurements .	13
3.5 Electronic Charge Measurements	13
4. DISCUSSIONS	13
4.1 Relationships with Other A2ARPhar Models	13
4.2 Planar Ring Region	16
4.3 Nitrogen Environment	18
4.4 Bridge Area Between the Compound's Planar Ring and Nitrogen Environment	19
4.5 A2ARPhar Region C	19
4.6 Hydrophobic Cleft or Lipophilic Region	20
4.7 Structure-Activity Relationships	20
4.8 Drug Design	20
5. CONCLUSIONS	23
LITERATURE CITED	25
APPENDIXES	
A. COMPOUND STRUCTURE FILE FORMAT	29
B. COMPOUND THREE-DIMENSIONAL COORDINATES	31

LIST OF FIGURES AND TABLES

FIGURES

1.	Alpha2-Adrenergic Agonists Analyzed	8
2.	Overlap of 14 Alpha2-Adrenergic Agonists	12
3.	The 14 Alpha2-Adrenergic Agonists Overlap Rotated 90°	13
4.	PM3 Alpha2-Adrenoceptor Pharmacophore Interaction Template	14
5.	PM3 Alpha2-Adrenoceptor Pharmacophore Template Rotated 90°	15
6.	Example of Intra-atomic Distance Measurements	16
7.	Example of Plane to Nitrogen and Proton Measurements	17
8.	Agonist-Adrenoceptor Pharmacophore Interaction Distance Measurements	18
9.	UK14304, YAI1085, and Clonidine Interaction with A2ARPhar .	21
10.	UK14304, YAI1085, and Clonidine Interaction with A2ARPhar Rotated 90°	22
11.	BHT920/A2ARPhar Interactions	24
12.	A62032/A2ARPhar Interactions	25

TABLE

Distance and Charge Measurements for Alpha2-Adrenergic Agonists	11
--	----

COMPUTER-ASSISTED DETERMINATION OF MINIMUM ENERGY CONFORMATIONS

VI. A PHARMACOPHORE MODEL OF THE ACTIVE REGION OF THE ALPHA2-ADRENOCEPTOR

1. INTRODUCTION

The adrenergic system is made up of a variety of receptor subtypes that have been differentiated into two main categories; alpha 1 and alpha 2.^{1,2,3} The physiological responses of compounds interacting on the system vary from increases and decreases in cardiovascular (i.e., heart rate, blood pressure) and respiratory functions to the ability to cause sedation and anesthesia. Timmermans⁴ and Savola⁵ discuss the classification and mechanisms of action of compounds on the various types of adrenergic receptors; and Ruffolo⁶ discusses structure-activity relationships (SAR) specifically with the alpha2-adrenergic system.

Alpha2-adrenergic agonists can be potent sedatives.^{7,8} Most important, anesthesia and sedation are produced by these agonists without the unwanted side effect of respiratory depression. Because of this physiological response, a molecular modeling and theoretical chemistry study was performed to develop a "pharmacophore model" of the alpha2-adrenergic receptor (adrenoceptor) active region for use in SAR studies and as a template in designing compounds having desired sedative and anesthetic activity. A proposed topography of the active region of the alpha2-adrenoceptor (A2AR) is defined.


2. EXPERIMENTATION

2.1 Compound Structures.

Fourteen compounds known to interact as agonists at the A2AR are analyzed. The compounds (Figure 1) are BHT920,³ BHT933,³ Clonidine,⁴ M-7,⁴ Guanabenz,⁴ Guanfacine,⁴ UK14304,⁴ Medetomidine,⁷ Noradrenaline,⁹ Alpha-methylnoradrenaline,⁹ YAII085,¹⁰ the stereoisomers of R-2-(5,6-dihydroxy-1,2,3,4-tetrahydro-1-naphthyl)imidazoline [A62032 (S)¹¹ and A62033 (R)¹¹] and Moxonidine.¹² The compounds represent 10 different classes that are composed of planar ring (mostly aromatic) and various nitrogen environments.


2.2 Three-Dimensional Minimum Energy Conformation Optimization.

The Chemometric/Biometric Modeling Branch, Research Directorate, U.S. Army Chemical Research, Development and Engineering Center (CRDEC) Molecular Modeling Analysis and Display System (MMADS) (Version 3.1)¹³ was used to incorporate the structures and perform the minimum energy and semi-empirical molecular orbital calculations.




A62032 (S)


A62033 (R)




BHT920




BHT933




YAI1085




Clonidine




Guanfacine




Guanabenz




Moxonidine




Noradrenaline




Alphamethylnoradrenaline



UK14304



Medetomidine



M-7

Figure 1. Alpha2-Adrenergic Agonists Analyzed

In the initial analysis, x-ray crystal coordinates were used for the following three compounds: noradrenaline,¹⁴ clonidine,¹⁵ and A62032.¹¹ The three-dimensional conformations of these compounds were used as templates to construct and incorporate the other compounds for MMADS three-dimensional conformation analysis. As the study progressed, the crystal structure (Unpublished results, 1991, Laboratory for the Structure of Matter, Naval Research Laboratories, Washington, DC) of YAI1085 was obtained. This structure was used in developing the final pharmacophore model.

Initially, conformational minimum energy calculations were performed to achieve molecular mechanics structure optimization¹⁶ (optimized geometries) using the empirical MM2 (Quantum Chemistry Program Exchange version dated 1980) computer program developed by Allinger and Yuh.¹⁷

Next, the MM2 Cartesian coordinates of each compound were used as starting coordinates for input into the MOPAC¹⁸ program for determining the molecular orbital optimized geometries of the unprotonated and protonated forms of each compound using the PM3 Hamiltonians.

The PM3 coordinates were then used as starting coordinates for MOPAC AM1¹⁸ calculations. A Digital Equipment Corporation (Maynard, MA) MicroVax II within a VMS operating system environment was used for the calculations.

2.3 Alpha2-Adrenoceptor Pharmacophore Development.

Identifying of the three-dimensional steric (geometric), physicochemical, and electrostatic parameters to be evaluated involved consultations with experts, literature searches, and analyses of compounds known to interact with the adrenergic system. Studies,^{1,3,10,11,19,20} especially those by Timmermans,⁴ Savola,⁵ Ruffolo,^{6,7,21} and Hancock,²² suggest specific structural and functional group requirements for compound interaction with the A2AR.

The MMADS was used to incorporate and manipulate (STICK option) the compounds. The Tektronix 4105 series color graphics computer terminal to graphically displayed the 14 structures and performed a molecular modeling analysis.

The crystal structure coordinates of noradrenaline, clonidine, and A62032 were used in all molecular modeling analyses (MM2, PM3, AM1).

Initially, the 3 crystal structures and the 11 unprotonated MM2 optimized structures were superimposed on each other with the common planar ring carbons overlapped. The MM2 optimized structure of the compound Medetomidine (R-form) was used as the starting molecule to which all others were oriented. The procedure was to superimpose a molecule to the "best" three-dimensional fit of the molecule's planar ring carbons and its nitrogen to that of Medetomidine's and then save the two overlapped molecules as the template for the next compound to be added. The next compound was added to the two compounds and overlapped similarly, and the three-compound overlap became the new template for the next compound to be added. This procedure

was reiterated until all 14 compounds were overlapped. As compounds were added, compound functional regions and geometric positions of common compound atoms were identified. The above process was reiterated, incorporating the identified common attributes until an initial pharmacophore model was developed.

The same procedure was followed using the AM1 and PM3 optimized geometries. After analysis, the compounds were then protonated at the nitrogen predicted to interact with the adrenoceptor and optimized for their protonated three-dimensional conformations. The same overlap procedure was used on the protonated PM3 and protonated AM1 optimized geometries.

In the final analysis, the crystal structure of YAI1085 replaced its PM3 and AM1 protonated structures. The final adrenoceptor pharmacophore was developed from the overlap of the 10 PM3 protonated structures and the 4 crystal structures.

3. RESULTS

3.1 Three-Dimensional Conformations of Selected Alpha2-Adrenergic Compounds.

The individual compound structure files, which list the 10 PM3 program calculated three-dimensional Cartesian atom coordinates corresponding to the minimum energy optimized geometry for the protonated conformations and the 4 x-ray crystal Cartesian atom coordinates that were used to determine the A2AR, are reported in Appendix B.

3.2 Alpha2-Adrenoceptor Pharmacophore Model (A2ARPhar).

Figures 2 and 3 (compounds rotated 90°) illustrate the results of the molecular modeling analysis of the overlap of the 14 A2AR agonists. Two regions (A, a planar ring system generally aromatic in functionality, and B, a region containing a nitrogen atom and its proton) are common to each agonist and are (or can be) positioned so that they overlap. A third region (C, although not common to all the compounds) may involve the interaction of the hydroxyl groups of A62032, A62033, noradrenaline, and alphanemethylnoradrenaline.

Figures 4 and 5 illustrate the topography and give the three-dimensional coordinates of a proposed A2ARPhar model developed from the overlap of the above compounds. The model identifies the following four distinct potential compound/receptor interaction regions: (a) Region A is a planar region that may involve lipophilic or pi-pi interactions; (b) Region B consists of an environment for compound proton/receptor interaction; (c) Region C is a region that provides potential interaction with a compound's hydroxyl or negatively charged functional groups. Region C may not exist in the A2AR subtype that produces sedation. However, there is insufficient data to eliminate region C; therefore, the model includes this region for use as an area to be studied in future research efforts. Region D is depicted in the




Figure 2. Overlap of 14 Alpha2-Adrenergic Agonists




Figure 3. The 14 Alpha2-Adrenergic Agonists Overlap Rotated 90°




Figure 4. PM3 Alpha2-Adrenoceptor Pharmacophore Interaction Template



Figure 5. PM3 Alpha2-Adrenoceptor Pharmacophore Template Rotated 90°

figures as a cloud that represents an area for lipophilic or hydrophobic binding. This area can accommodate functional groups that are lipophilic (i.e., halides, hydrophobic carbon containing groups).

3.3 Intra-Atomic Distances and Angles.

Figures 6 and 7 illustrate intra-atomic distances that were measured using the MMADS Bond option of the MMADS EDIT routine. The distances were as follows: (a) the distance from the center of the planar ring of the compound to the nitrogen whose proton was predicted to interact with the adrenoceptor (A); (b) the distance from the center of the planar ring to the proton (B); (c) the distance from the plane of the planar ring to the nitrogen (C); and (d) the distance from the ring plane to the proton (D).

Additional compound measurements were made of the angle formed by the center of the planar ring, the above selected nitrogen, and its proton.

The Table gives the measurements for the distances and angles for the 14 compounds.

3.4 Agonist-A2ARPhar Interaction Distance Measurements.

Figure 8 illustrates the distances (E) from the nitrogen of the agonist to the proposed proton binding region of the pharmacophore and (F) from the agonist's proton to this pharmacophore region. The Table lists the measured distances.

3.5 Electronic Charge Measurements.

The Table lists the electronic charge units (PM3 Charge NH+) of each compound for the nitrogen proton environment that is predicted to interact with the A2AR. The unit is calculated by adding the PM3 formal charges of the nitrogen and its bonded hydrogen that the molecular modeling analysis predicted to interact with the A2AR.

4. DISCUSSIONS

4.1 Relationships with Other A2ARPhar Models.

Molecular modeling studies to predict the environment of the A2AR receptor environment are limited to a small number of selective agonist classes (phenethylamines, clonidine-type imidazoles) or involved antagonists. Reviews by Ruffolo,⁶ Savola,⁵ and Guptka¹⁹ discuss the various SARs with various classes of alpha2-adrenergic compounds and describe model pharmacophores for compound receptor interactions. This study has evaluated the models of Ruffolo⁶, Hancock,²² Kier,²³ Pullman,²⁴ Easson-Stedman,²⁵ and Timmermans.²⁶

Table. Distance and Charge Measurements for Alpha2-Adrenergic Agonists

Compound Name	Center to N	Center to H+	Plane to N	Plane to H+	Angle (Center-N-H+)	A2ARPHar to N	A2ARPHar to H+	PM3 Charge (NH+)
	(A)	(B)	(C)	(D)		(E)	(F)	
A62032 (S)	4.73	5.01	0.05	-1.01	98.7	2.483	2.507	0.34
A62033 (R)	4.94	5.39	-0.90	-0.07	111.8	2.769	2.925	0.31
BHT920	4.21	4.80	0.04	-0.66	120.5	2.103	1.327	0.67
BHT933	4.08	4.67	0.03	-0.66	120.8	2.035	1.231	0.67
Clonidine	5.00	5.49	-0.98	-0.11	111.2	1.351	0.965	0.31
Guanabenz	5.16	5.48	0.09	-0.80	103.7	0.872	0.277	0.13
Guanfacine	5.23	5.59	-1.10	-0.81	106.0	1.001	0.283	0.11
M-7	5.19	5.35	0.41	0.68	93.5	2.098	1.523	0.72
Medetomidine	5.12	5.63	-1.40	-0.69	116.8	1.097	0.180	0.56
Moxonidine	5.13	5.55	-1.74	-1.03	114.1	1.448	0.503	0.23
Noradrenaline	5.17	5.58	-1.16	-0.57	110.1	1.307	0.499	0.93
Alphamethyl-Noradrenaline	5.15	5.47	-1.53	-1.28	103.1	1.570	0.809	0.86
UK14304	5.10	5.43	-0.52	-0.50	104.1	1.109	0.156	0.33
YAI1085	5.09	5.65	-1.41	-0.66	116.2	1.158	0.250	0.54

NOTES:

Distances are measured in Angstrom units.

The PM3 charge is the electrostatic charge environment measured by adding the formal charge of the compound's nitrogen and hydrogen closest to the predicted adrenoceptor negative region. It is measured in electronic charge units.




Figure 6. Example of Intra-Atomic Distance Measurements




Figure 7. Example of Plane to Nitrogen and Proton Measurements

Compound Overlaped with Pharmacophore




Figure 8. Agonist-Adrenoceptor Pharmacophore Interaction Distance Measurements

An additional model by Lloyd and Andrews²⁷ defining a common structural model for central nervous system compounds was also evaluated. Our molecular modeling analysis of alpha2-adrenergic agonists supports these findings.

Our A2ARPhar model incorporates many of the same features as previous models; but, our study specifically addresses alpha2-adrenergic agonists and provides additional insight to the importance of the position of the compound's proton in resultant agonist activity. Our model also provides three-dimensional Cartesian coordinates of a proposed A2AR environment that can be used as a compound/receptor interaction template for future structure-activity studies.

The following three compound regions are common to all the proposed models (including our A2ARPhar): (a) a planar ring; (b) a nitrogen environment; and (c) a bridge region that separates the planar ring system from the nitrogen region.

4.2 Planar Ring Region.

Figure 1 illustrates the various planar ring systems (mainly aromatic) that can interact with the A2AR. Figures 2 and 3 illustrate the planarity of the ring systems for the various types of rings and show that the

rings can be overlapped in a common orientation (Region A). This type of compound/receptor interaction could involve charge transfer interactions, ion-induced dipole, or lipophilic binding. The molecular analysis suggests that one may be limited in the position, size, and type of the substituent on the planar ring to maintain agonist activity. Previous studies^{5,6,19} described SARs for substituents on the ring systems for a variety of classes of compounds. We propose that in developing SARs for alpha2 agonists that investigators orient the planar ring system as illustrated in our model; the same relationships will generally hold for other planar ring systems. Hancock²² provides some insight as to the spatial domains necessary to maintain agonist activity. In our study, the agonists studied fit these domains. Two compounds not analyzed in the previous studies, UK14304 and YAI1085, extend the domain of the planar ring system. The YAI1085 compound was specifically designed to evaluate the spatial domain and lipophilic region of the model. Figures 9 and 10 illustrate the increased spatial domain of the planar region for the interaction of these compounds and for the interaction of clonidine with the A2ARPhar model.




Figure 9. UK14304, YAI1085, and Clonidine Interaction with A2ARPhar




Figure 10. UK14304, YAI1085, and Clonidine Interaction with A2ARPHar Rotated 90°

4.3 Nitrogen Environment.

Figure 1 illustrates the alpha2-adrenergic agonists various nitrogen environments. The compound nitrogen environment/receptor interaction may involve ionic, ion-induced dipole, or noncoulombic van der Waals types.

Previous studies^{5,6,20,23,24,27} suggest that agonist activity relates to the distance (see Table, Column A) from the center of the planar ring system to the nitrogen is predicted to interact with the receptor. Additionally, the distance (see Table, Column C) from the plane formed by the ring system to the nitrogen was suggested for measurement as a potential for identifying a feature common to alpha2-adrenergic agonists. The Table lists the above measured distances (Columns A and C) for the agonists studied. The center of ring to the nitrogen distance varied from 4.21 Å for BHT920 to 5.31 Å for M-7. The plane to nitrogen distance varied from 0.41 Å for M-7 to -1.75 Å for Moxonidine.

Although all of the compounds are agonists at the A2AR, there are differences in the degree of their action. In analyzing the above measurements for the A2ARPHar model development, the distance variation did not allow for a quantitative positioning of the pharmacophore interaction region (Figures 4 and 5, Region B). Therefore, since these compounds may protonate at physiological pH, the compounds were protonated and another molecular analysis was performed. The analysis identified that the protonated species of the agonists BHT920, BHT933, Medetomidine, Moxonidine, UK14304, and the crystal structures of Noradrenaline and YAI1085 had a common plane to H⁺ distance of -0.66 ± 0.1 (-0.56 to -0.76) Å. Important to note is that although the nitrogen for these compounds is located in different

three-dimensional positions, the protons are all positioned so that they lie in the same plane. Additionally, the protons are directed away from the center of the planar ring (indicated by the angle (in the Table, Center-N-H+), which would orient the proton for "best interaction" with the A2AR).

Figures 2, 3, 9, and 10 illustrate the above relationship. The protons are represented as the smallest circles seen near the B region. The figures show the bond between the proton and its nitrogen and the direction of the proton towards Region B.

Because of these observations, additional measurements were made to identify the distances (see Table, Columns E and F) from our proposed A2ARPHar model to the nitrogen of the agonists and the proton to evaluate how the compounds would interact with the A2ARPHar model. In the overlap orientation, the protons of compounds A62032, A62033, BHT920, BHT933, and M-7 are positioned at distances (see Table, Column F) $>1.2 \text{ \AA}$ from the proposed A2ARPHar region. If one overlapped them, as in the original analysis, the compounds would not fit geometrically to interact with Region B of the A2ARPHar model. Investigators would propose that the better the compounds fit (geometrically, physicochemically, and electrostatically) to Regions A and B of the pharmacophore, the more enhanced their activity would be.

Compounds BHT920 and BHT933 are selective α_2 -adrenergic agonists. One can position BHT920 and BHT933 to interact more closely to Region B by simply moving the compounds in the x direction. Their protons are situated at the appropriate ring to planar distance $-0.67 \text{ \AA}$. Figure 11 illustrates the resultant BHT920/A2ARPHar interaction.

Similarly, a better fit of A62032, A62033, and M-7 can be obtained by rotating each molecule around Region B. Figure 12 illustrates the resultant A62032/A2ARPHar interaction.

4.4 Bridge Area Between the Compound's Planar Ring and Nitrogen Environment.

Ruffolo⁶ and Savola⁵ describe the various atom types that can be used to separate the planar ring system and the nitrogen of the α_2 -adrenergic agonists. The most important characteristics for resultant activity follow: (1) the ability of the bridge to orient the proton of the compound at the corresponding three-dimensional position for interaction with the A2AR, and (2) the substitution at the bridge regions that may change the formal charge in the nitrogen environment or may sterically hinder the proton from interacting properly with the A2AR.

4.5 A2ARPHar Region C.

Region C of the A2ARPHar is proposed for possible hydrogen bonding interaction for certain α_2 -adrenergic agonists. However, there is not enough data to quantitatively determine if this region exists in all the subtypes of A2ARs; the region may exist in postsynaptic or peripheral A2AR's but not in central or presynaptic A2ARs.

This region in the A2ARPhar model is suggested for future analysis.

4.6 Hydrophobic Cleft or Lipophilic Region.

The proposed A2ARPhar hydrophobic cleft or lipophilic region (Figures 4 and 5) is similar to the proposed lipophilic/aromatic region proposed by Ruffolo.⁶ This study that includes Savola's compounds⁵ and the YAI1085 compound¹⁰ extends the geometric dimensions of this region. Generally, the study extends the dimensions of the planar ring system from a small phenyl type to include a region that can accommodate a naphthalene ring.

4.7 Structure-Activity Relationships.

The proposed A2ARPhar model can be used for in vitro ligand binding and in vivo physiological studies as a "pharmacophore" template for analyzing compounds that act on the A2AR, for better defining the environment of the A2AR, and for use in designing of compounds having desired pharmacological effects. The model can be used to identify compound functional groups in relation to potential interaction areas on the receptor template; thereby, investigators can use more efficient structure-activity methods to analyze congeneric series of alpha2-adrenergic compounds.

We suggest protonating the compound at the nitrogen environment for a proposed interaction with the A2AR. Next, we suggest reconstructing the proposed pharmacophore and initially orienting each compound to be analyzed to the A2RPhar planar ring Region A. Each compound's ring system should be directly overlapped. After overlapping, the pharmacophore should be raised 0.7 Å above the compound's ring as shown in Figures 10 and 11. This repositioning allows for appropriate contact atom bond radii for interaction of the compound with the proposed pharmacophore.

Researchers should then note the position of the proton in relationship to Region B. Positioning of the molecule would then be used as part of the overall structure-activity analysis.

4.8 Drug Design.

The A2ARPhar model can be used in drug design and structure-activity studies in the following ways: (a) to identify parameters of tested compounds for isolation of features related to alpha2-adrenergic activity; (b) to recommend new compounds for experimentation, incorporating structural and physicochemical features suggested by the model; (c) to identify new directions (new lead series of compounds) that may increase drug efficacy or improve the current pharmacophore model; and (d) to aid in an improved understanding of the mechanisms and structural models of the alpha2-adrenergic system as related to the pharmacological action of compounds.




Figure 11. BHT920/A2ARPHar Interactions

1. BHT920 Overlapped on A2ARPHar Region A
2. BHT920 Moved Towards Region B




Figure 12. A62032/A2ARPHar Interactions

1. A62032 Overlapped on A2ARPHar Region A
2. A62032 Rotated on Region A

5.

CONCLUSIONS

A pharmacophore model of an alpha2-adrenergic receptor agonist environment is defined in relation to the physicochemical and three-dimensional structural features of compounds known to be agonists with the alpha2-adrenoceptor. Also, important to the agonist activity of the compounds is the position of a proton of the compound's protonated form in relation to the center of its planar ring.

The model can be used as a drug-receptor interaction template in structure-activity, biochemical ligand binding, and drug design studies for correlation and/or recommendation of new compounds having improved pharmacological action.

Blank

LITERATURE CITED

1. van Zwieten, P.A., and Timmermans, P.B., "Central and Peripheral Alpha-Adrenoceptors, Pharmacological Aspects and Clinical Potential," Ad. Drug Res. Vol. 13, pp 209-254 (1984).
2. Bylund, D.B., and Ray-Prenger, C., "Alpha-2A and Alpha-2B Adrenergic Receptor Subtypes: Attenuation of Cyclic AMP Production in Cell Lines Containing only One Receptor Subtype," J. Pharmacol. Exp. Ther. Vol. 251 (2), pp 640-644 (1989).
3. Kobinger, W., "Drugs as Tools in Research on Adrenoceptors," Arch. Pharmacol. Vol. 332, pp 113-123 (1986).
4. Timmermans, P.B., and van Zwieten, P., "Alpha2 Adrenoceptors: Classification, Localization, Mechanisms, and Targets for Drug Action," J. Med. Chem. Vol. 25 (12), pp 1389-1401 (1982).
5. Savola, J., "Cardiovascular and Sedative Effects of Novel Detomidine-like Arylalkyl Imidazoles and Related Derivatives, Acta Univ. Palack. Olomuc., Series D, Medica No. 147, Pharmacologica Et Physiologica No. 25 (1986).
6. Ruffolo, R.R., Jr., De Marinis, R.M., Wise, M., and Hieble, J.P., "Structure-Activity Relationships for Alpha2-Adrenergic Receptor Agonists and Antagonists," In The Alpha2-Adrenergic Receptors, L.E. Limbird, Editor, pp 115-187, Human Press, Clifton, NJ, 1988.
7. Scheinin, M., Kallio, A., Koulu, M., Viikari, J., and Scheinin, H., "Sedative and Cardiovascular Effects of Medetomidine, a Novel Alpha2-Adrenoceptor Agonist, in Healthy Volunteers," Br. J. Clin. Pharmacol. Vol. 24, pp 443-451 (1987).
8. Bloor, B., and Flacke, W.E., "Reduction in Halothane Anesthetic Requirement by Clonidine, An Alpha Adrenergic Agonist," Anesth. Analg. Vol. 41, pp 741-745 (1982).
9. Ruffolo, R.R., Jr., "Stereochemical Requirement for Activation and Blockade of Alpha1 and Alpha2 Adrenoceptors," In Trends in Pharmaceutical Science (TIPS), pp 160-164, 1984.
10. Amemiya, Y., Hsu, F., Shams, G., Feller, D.R., Ventkataraman, B.V., Patil, P.N., and Miller, D.D., "Medtomidine Analogs as Alpha-Adrenergic Agonists," In Proceedings of the U.S. Army Chemical Research, Development and Engineering Center Scientific Conference on Chemical Defense, CRDEC-SP-024, U.S. Army Chemical Research, Development and Engineering Center, Aberdeen Proving Ground, MD, August 1990, UNCLASSIFIED Report (A229 414).

11. DeBarnadis, J.F., Kerkman, D.J., Andersen, D.L., Buckner, S.A., Kyncl, J.J., and Hancock, A.A., "Conformationally Define Adrenergic Agents, 5. Resolution, Absolute Configuration, and Pharmacological Characterization of the Enantiomers of 2-(5,6-Dihydroxy-1,2,3,4-tetrahydro-1-naphthyl)imidazoline: A Potent Agonist at Alpha-Adrenoceptor," J. Med. Chem. Vol. 30, pp 1011-1017 (1987).
12. Petrello, E.W., Trippodo, N.C., and DeForrest, J.M., "Chapter 6. Antihypertensive Agents, Section II. Cardiovascular and Pulmonary Agents," Annu. Rep. Med. Chem. Vol. 25, p 57 (1990).
13. Leonard, J.M., and Famini, G.R., A User's Guide to the Molecular Modeling, Analysis, and Display System (MMADS), CRDEC-TR-030, U.S. Army Chemical Research, Development and Engineering Center, Aberdeen Proving Ground, MD, January 1989, UNCLASSIFIED Report (A205 674).
14. Andersen, A.M., "Structural Studies of Metabolic Products of Dopamine, IV. Crystal and Molecular Structure of (-)-Noradrenaline," Acta Chem. Scand. Vol. B29 (8), pp 871-876 (1975).
15. Byre, G., Mostad, A., and Romming, C., "Crystal and Molecular Structure of Clonidine Hydrochloride, 2-(2,6-Dichlorophenylamino)-2-imidazoline Hydrochloride," Acta Chem. Scand. Vol. B30 (9), pp 844-846 (1976).
16. Burket, U., and Allinger, N.L., Molecular Mechanics, ACS Monograph 177, American Chemical Society, Washington, DC, 1982.
17. Allinger, N.L., and Yuh, Y.H., Quantum Chemistry Exchange (OPCE Program), Vol. 13, p 395 (1980).
18. Stewart, J.J.P., MOPAC Manual (Fifth Edition): A General Molecular Orbital Package, FJSRL-TR-88-007, Frank J. Seiler Research Laboratory, U.S. Air Force Academy, Colorado Springs, CO, December 1988, UNCLASSIFIED Report.
19. Gupta, S.P., "QSAR Studies on Drugs Acting at the Central Nervous System," Chem. Rev. Vol. 89 (8), pp 1765-1800 (1989).
20. Giesecke, J., and Herbert, H., "The Molecular Structure of Adrenergic and Dopaminergic Substances," Quarterly Reviews of Biophysics Vol. 12 (3), pp 263-313 (1979).
21. Ruffolo, R.R., Jr., "Structure-Activity Relationships of Alpha-Adrenoceptor Agonist and Antagonists," Adrenoceptors: Structure, Mechanisms, Function, Birkhauser Verlag, Berlin, pp 5-14 (1991).
22. Hancock, A.A., Kyncl, J.J., Martin, Y.C., and DeBarnadis, J.F., "Differentiation of Alpha-Adrenergic Receptors Using Pharmacological Evaluation and Molecular Modeling of Selective Adrenergic Receptor," J. Rec. Res. Vol 8 (1-4), pp 23-46 (1988).

23. Kier, L.B., "The Preferred Conformations of Ephedrine Isomers and the Nature of the Alpha Adrenergic Receptor," J. Pharmacol. Exp. Ther. Vol. 164 (1), pp 75-81 (1968).
24. Pullman, B., Coubils, J.L., Courriere, P., and Gervois, J.P., "Quantum Mechanical Study of the Conformational Properties of Phenethylamines of Biochemical Interest," J. Med. Chem. Vol. 15 (1), pp 17-23 (1972).
25. Kasson, L.H., and Stedman, E., "Studies on the Relationship Between Chemical Constitution and Physiological Action, V. Molecular Dissymmetry and Physiological Activity," Biochemistry Journal Vol. 27, pp 1257-1266 (1933).
26. Timmermans, P.B.M., Hoefke, W., Stahle, H., and van Zwieten, P.A., Prog. Pharmacol. Vol. 3, pp 1 (1980).
27. Lloyd, E.J., and Andrews, P.R., "A Common Structural Model for Central Nervous Drugs and Their Receptors," J. Med. Chem. Vol. 29 (4), pp 453-462 (1986).

Blank

APPENDIX A
COMPOUND STRUCTURE FILE FORMAT

The compound structure file is the primary data structure of MMADS, containing all of the required molecular information. The data records contained in the chemical compound structure file are listed below.

Record #1 - the header record for the file

Column Nos. 1-3 The number of atoms contained in the file

Column Nos. 4-72 The title of the structure file

Record #2 - The descriptions of the individual atoms

Column No. - 1 Blank

Column Nos. 2-3 The atom symbol

Column Nos. 4-8 The atom index

Column Nos. 9-20 The x-coordinate

Column Nos. 21-32 The y-coordinate

Column Nos. 33-44 The z-coordinate

Column Nos. 45-49 The atom type (defined below)

Column Nos. 50-79 The atom bond connectivity

MMADS uses the atom type to encode information describing each atom's molecular environment. The atom types used by MMADS are defined below:

<u>Atom Type</u>	<u>Atom Type Description</u>
1	Carbon - sp3
2	Carbon - sp2
3	Carbonyl Carbon
4	Carbon - sp
5	Hydrogen
6	Oxygen - sp3
7	Oxygen - sp2
8	Nitrogen - sp3

<u>Atom Type</u>	<u>Atom Type Description</u>
9	Nitrogen - sp ²
10	Nitrogen - sp
11	Fluorine
12	Chlorine
13	Bromine
14	Iodine
15-18	Sulfur (in development)
19	Silicon
20	(inactive)
21	Alcoholic Hydrogen (N-H, O-H)
22	Cyclopropane Hydrogen
23	Amine Hydrogen
24	Carboxyl Hydrogen
25	Phosphorus

APPENDIX B
COMPOUND THREE-DIMENSIONAL COORDINATES

A62032 (S) CRYSTAL				H18							
C	1	-0.142032	-1.005426	-0.485563	1	2	10	14	19	35	0
C	2	-1.474451	-1.551968	0.085989	1	1	3	20	21	0	0
C	3	-2.614692	-0.892071	-0.616703	1	2	4	22	23	0	0
C	4	-2.683625	0.591357	-0.342558	1	3	5	24	25	0	0
C	5	-1.323117	1.260984	-0.424872	2	4	6	10	0	0	0
C	6	-1.231141	2.661258	-0.452624	2	5	7	11	0	0	0
C	7	-0.008813	3.324809	-0.449451	2	6	8	12	0	0	0
C	8	1.123600	2.578927	-0.429900	2	7	9	26	0	0	0
C	9	1.071557	1.201987	-0.455376	2	8	10	27	0	0	0
C	10	-0.143500	0.533147	-0.442824	2	1	5	9	0	0	0
O	11	-2.413177	3.366037	-0.571941	6	6	28	0	0	0	0
O	12	-0.082530	4.679329	-0.473058	6	7	29	0	0	0	0
N	13	1.894428	-2.364099	-0.391689	9	14	17	18	0	0	0
C	14	1.004077	-1.606520	0.223079	2	1	13	15	0	0	0
N	15	1.258124	-1.448641	1.514812	8	14	16	30	0	0	0
C	16	2.486379	-2.155879	1.880076	1	15	17	31	32	0	0
C	17	2.845099	-2.915977	0.561670	1	13	16	33	34	0	0
H	18	1.914114	-2.548556	-1.455639	23	13	0	0	0	0	0
H	19	-0.082709	-1.339945	-1.521266	5	1	0	0	0	0	0
H	20	-1.523861	-2.629545	-0.070496	5	2	0	0	0	0	0
H	21	-1.529468	-1.336358	1.153034	5	2	0	0	0	0	0
H	22	-2.498573	-1.043895	-1.689813	5	3	0	0	0	0	0
H	23	-3.544433	-1.352556	-0.282583	5	3	0	0	0	0	0
H	24	-3.344989	1.052095	-1.076327	5	4	0	0	0	0	0
H	25	-3.088168	0.743501	0.658091	5	4	0	0	0	0	0
H	26	2.083385	3.072794	-0.393719	5	8	0	0	0	0	0
H	27	1.990468	0.635338	-0.485560	5	9	0	0	0	0	0
H	28	-3.043943	3.205294	-1.408539	21	11	0	0	0	0	0
H	29	0.377140	5.248578	0.293924	21	12	0	0	0	0	0
H	30	0.646420	-0.879730	2.199326	23	15	0	0	0	0	0
H	31	3.275082	-1.456934	2.158512	5	16	0	0	0	0	0
H	32	2.310737	-2.851870	2.700347	5	16	0	0	0	0	0
H	33	2.706983	-3.990978	0.677413	5	17	0	0	0	0	0
H	34	3.871455	-2.711749	0.256738	5	17	0	0	0	0	0

A62033 PROTONATED H29											
C	1	0.095820	-0.957101	0.664294	1	2	10	13	25	0	0
C	2	-1.225130	-1.718079	0.483396	1	1	3	14	15	0	0
C	3	-2.352289	-1.012366	1.211594	1	2	4	16	17	0	0
C	4	-2.550280	0.377394	0.636813	1	3	5	18	19	0	0
C	5	-1.284238	1.171352	0.637779	2	4	6	10	0	0	0
C	6	-1.338986	2.575383	0.660659	2	5	7	11	0	0	0
C	7	-0.148409	3.340489	0.631343	2	6	8	12	0	0	0
C	8	1.093052	2.688802	0.639320	2	7	9	20	0	0	0
C	9	1.136797	1.304589	0.653989	2	8	10	21	0	0	0
C	10	-0.033604	0.540488	0.621928	2	1	5	9	0	0	0
O	11	-2.508086	3.289346	0.695560	6	6	22	0	0	0	0
O	12	-0.096442	4.697387	0.597333	6	7	23	0	0	0	0
H	13	0.520794	-1.213706	1.669853	5	1	0	0	0	0	0
H	14	-1.484958	-1.814685	-0.589920	5	2	0	0	0	0	0
H	15	-1.113832	-2.752814	0.862096	5	2	0	0	0	0	0
H	16	-3.287909	-1.598750	1.119453	5	3	0	0	0	0	0
H	17	-2.133939	-0.959453	2.297360	5	3	0	0	0	0	0
H	18	-2.927299	0.313544	-0.404764	5	4	0	0	0	0	0
H	19	-3.340242	0.914922	1.208751	5	4	0	0	0	0	0
H	20	2.021036	3.274508	0.650057	5	8	0	0	0	0	0
H	21	2.114031	0.810544	0.710694	5	9	0	0	0	0	0
H	22	-3.214995	2.684407	0.911166	21	11	0	0	0	0	0
H	23	-0.977873	5.050347	0.620414	21	12	0	0	0	0	0
N	24	1.088233	-0.953881	-1.685144	8	25	28	34	0	0	0
C	25	1.052399	-1.419788	-0.408096	2	1	24	26	0	0	0
N	26	1.996011	-2.390540	-0.260052	8	25	27	29	0	0	0
C	27	2.789187	-2.602435	-1.509821	1	26	28	30	31	0	0
C	28	2.179231	-1.587740	-2.487078	1	24	27	32	33	0	0
H	29	2.149399	-2.905238	0.574822	23	26	0	0	0	0	0
H	30	3.867960	-2.428438	-1.316440	5	27	0	0	0	0	0
H	31	2.696900	-3.651934	-1.857267	5	27	0	0	0	0	0
H	32	1.758739	-2.057811	-3.399386	5	28	0	0	0	0	0
H	33	2.907753	-0.826697	-2.833230	5	28	0	0	0	0	0
H	34	0.551172	-0.182045	-2.007481	23	24	0	0	0	0	0

BHT920 PROTONATED H3O

S	1	-0.771936	3.560297	-0.511761	15	2	5	0	0	0	0
C	2	-2.486437	3.118230	-0.481858	2	1	3	13	0	0	0
N	3	-2.700613	1.783118	-0.458927	9	2	4	0	0	0	0
C	4	-1.493360	1.072516	-0.450361	2	3	5	12	0	0	0
C	5	-0.366011	1.863278	-0.483076	2	1	4	11	0	0	0
C	6	-0.437676	-1.079665	-1.174430	1	7	12	14	15	0	0
N	7	0.896790	-1.136522	-0.434753	8	6	8	9	30	0	0
C	8	1.238634	0.136700	0.330822	1	7	11	16	17	0	0
C	9	0.947689	-2.345359	0.503393	1	7	10	18	19	0	0
C	10	2.345279	-2.606509	0.946296	2	9	20	21	0	0	0
C	11	1.041835	1.405349	-0.492603	1	5	8	23	24	0	0
C	12	-1.565307	-0.413771	-0.397534	1	4	6	25	26	0	0
N	13	-3.563597	3.986429	-0.362282	8	2	27	28	0	0	0
H	14	-0.286270	-0.540191	-2.137373	5	6	0	0	0	0	0
H	15	-0.730191	-2.118186	-1.450305	5	6	0	0	0	0	0
H	16	0.624780	0.189844	1.259087	5	8	0	0	0	0	0
H	17	2.295006	0.049801	0.671923	5	8	0	0	0	0	0
H	18	0.258183	-2.175303	1.361707	5	9	0	0	0	0	0
H	19	0.558858	-3.243564	-0.028468	5	9	0	0	0	0	0
C	20	2.699816	-2.606199	2.228028	2	10	22	29	0	0	0
H	21	3.064564	-2.880426	0.161655	5	10	0	0	0	0	0
H	22	2.016866	-2.379441	3.045028	5	20	0	0	0	0	0
H	23	1.396007	1.272860	-1.537866	5	11	0	0	0	0	0
H	24	1.690491	2.197458	-0.061382	5	11	0	0	0	0	0
H	25	-1.594406	-0.748087	0.662028	5	12	0	0	0	0	0
H	26	-2.529175	-0.754936	-0.836158	5	12	0	0	0	0	0
H	27	-4.458656	3.605021	-0.559130	23	13	0	0	0	0	0
H	28	-3.409694	4.896589	-0.723214	23	13	0	0	0	0	0
H	29	3.711494	-2.846322	2.548246	5	20	0	0	0	0	0
H	30	1.607037	-1.263010	-1.136732	23	7	0	0	0	0	0

BH1933 PROTONATED H29											
O	1	-0.445639	2.442667	-0.211817	6	2	5	0	0	0	0
C	2	-1.826241	2.366191	-0.205258	2	1	3	13	0	0	0
N	3	-2.249347	1.084846	-0.194259	9	2	4	0	0	0	0
C	4	-1.089523	0.283622	-0.186254	2	3	5	12	0	0	0
C	5	-0.000493	1.122623	-0.198819	2	1	4	11	0	0	0
C	6	0.083529	-1.758363	-0.935373	1	7	12	14	15	0	0
N	7	1.408967	-1.737622	-0.168576	8	6	8	9	29	0	0
C	8	1.690008	-0.458054	0.616032	1	7	11	16	17	0	0
C	9	1.489906	-2.955791	0.754219	1	7	10	18	19	0	0
C	10	2.874330	-3.180030	1.324842	1	9	20	21	28	0	0
C	11	1.445910	0.829624	-0.169214	1	5	8	22	23	0	0
C	12	-1.114657	-1.194539	-0.176016	1	4	6	24	25	0	0
N	13	-2.565779	3.541778	-0.077151	8	2	26	27	0	0	0
H	14	0.218248	-1.187882	-1.883300	5	6	0	0	0	0	0
H	15	-0.124542	-2.809875	-1.239118	5	6	0	0	0	0	0
H	16	1.069368	-0.455966	1.541951	5	8	0	0	0	0	0
H	17	2.749331	-0.495779	0.960163	5	8	0	0	0	0	0
H	18	0.742478	-2.838935	1.570898	5	9	0	0	0	0	0
H	19	1.168421	-3.854157	0.178808	5	9	0	0	0	0	0
H	20	2.896472	-4.138430	1.865082	5	10	0	0	0	0	0
H	21	3.169178	-2.404943	2.048263	5	10	0	0	0	0	0
H	22	1.855832	0.772795	-1.199515	5	11	0	0	0	0	0
H	23	1.998420	1.656520	0.325539	5	11	0	0	0	0	0
H	24	-1.162863	-1.570145	0.868499	5	12	0	0	0	0	0
H	25	-2.044726	-1.559467	-0.662734	5	12	0	0	0	0	0
H	26	-3.523599	3.424987	-0.312549	23	13	0	0	0	0	0
H	27	-2.140103	4.336607	-0.492187	23	13	0	0	0	0	0
H	28	3.652651	-3.235304	0.549506	5	10	0	0	0	0	0
H	29	2.137625	-1.824352	-0.857453	23	7	0	0	0	0	0

CLONIDINE CRYSTAL H16											
CL	1	0.595701	2.416811	1.109814	12	7	0	0	0	0	0
CL	2	-2.022835	-2.298600	1.073673	12	11	0	0	0	0	0
N	3	0.411976	-0.587613	1.103078	9	6	12	0	0	0	0
N	4	0.945424	-0.211651	-1.156714	8	12	13	15	0	0	0
N	5	2.367600	-1.325500	0.077219	8	12	14	16	0	0	0
C	6	-0.823729	0.107530	1.072460	2	3	7	11	0	0	0
C	7	-0.872814	1.497719	1.078640	2	1	6	8	0	0	0
C	8	-2.076544	2.176974	1.068875	2	7	9	17	0	0	0
C	9	-3.260002	1.472635	1.052359	2	8	10	18	0	0	0
C	10	-3.246675	0.101555	1.058996	2	9	11	19	0	0	0
C	11	-2.037475	-0.574622	1.068978	2	2	6	10	0	0	0
C	12	1.199987	-0.709344	0.041262	2	3	4	5	0	0	0
C	13	2.038737	-0.489095	-2.068505	1	4	14	20	21	0	0
C	14	3.041583	-1.258321	-1.201621	1	5	13	22	23	0	0
H	15	0.047276	0.327187	-1.420122	23	4	0	0	0	0	0
H	16	2.768847	-1.817490	0.950916	23	5	0	0	0	0	0
H	17	-2.089061	3.256888	1.074181	5	8	0	0	0	0	0
H	18	-4.201286	2.001832	1.034124	5	9	0	0	0	0	0
H	19	-4.175579	-0.449382	1.056452	5	10	0	0	0	0	0
H	20	1.701371	-1.098170	-2.907141	5	13	0	0	0	0	0
H	21	2.477185	0.435658	-2.443597	5	13	0	0	0	0	0
H	22	3.985780	-0.719760	-1.120735	5	14	0	0	0	0	0
H	23	3.224532	-2.255242	-1.602594	5	14	0	0	0	0	0

GUANABENZ PROTONATED H21

N	1	1.734694	-2.125162	-0.282222	8	2	5	21	23	0	0
C	2	2.699888	-1.736751	0.826677	2	1	3	15	0	0	0
N	3	2.557563	-2.373870	1.927675	9	2	4	0	0	0	0
H	4	3.119972	-2.204319	2.719362	23	3	0	0	0	0	0
N	5	0.460777	-1.414577	-0.287872	9	1	12	0	0	0	0
C	6	-0.921901	0.544477	-0.373275	2	7	11	12	0	0	0
C	7	-2.156468	-0.134990	-0.375234	2	6	8	18	0	0	0
C	8	-3.360981	0.577995	-0.376407	2	7	9	19	0	0	0
C	9	-3.359977	1.963782	-0.373947	2	8	10	20	0	0	0
C	10	-2.148863	2.658484	-0.376747	2	9	11	13	0	0	0
C	11	-0.950927	1.961252	-0.381597	2	6	10	14	0	0	0
C	12	0.365606	-0.106124	-0.355651	2	5	6	22	0	0	0
H	13	-2.142029	3.756508	-0.375448	5	10	0	0	0	0	0
CL	14	0.473725	2.860514	-0.388912	12	11	0	0	0	0	0
N	15	3.576444	-0.642659	0.451200	8	2	16	17	0	0	0
H	16	4.411365	-0.994342	0.032225	5	15	0	0	0	0	0
H	17	3.783584	-0.063560	1.235359	5	15	0	0	0	0	0
CL	18	-2.264555	-1.797900	-0.374378	12	7	0	0	0	0	0
H	19	-4.309749	0.024726	-0.376743	5	8	0	0	0	0	0
H	20	-4.307574	2.517039	-0.371438	5	9	0	0	0	0	0
H	21	2.180727	-1.999456	-1.171558	23	1	0	0	0	0	0
H	22	1.260575	0.549418	-0.396652	5	12	0	0	0	0	0
H	23	1.447957	-3.082319	-0.178216	23	1	0	0	0	0	0

GUANFACINE PROTONATED H25

N	1	1.831767	-1.416907	-0.462561	9	2	5	21	0	0	0
C	2	2.988440	-1.096314	-1.175990	2	1	3	15	0	0	0
N	3	3.301145	0.232540	-1.396034	8	2	4	25	0	0	0
H	4	3.989292	0.452147	-2.079639	23	3	0	0	0	0	0
C	5	0.576510	-0.584940	-0.507807	2	1	12	24	0	0	0
C	6	-1.359530	0.338237	0.818402	2	7	11	12	0	0	0
C	7	-1.371655	1.738128	0.820145	2	6	8	18	0	0	0
C	8	-2.566200	2.452449	0.869047	2	7	9	19	0	0	0
C	9	-3.776356	1.767760	0.926803	2	8	10	20	0	0	0
C	10	-3.790605	0.377293	0.919220	2	9	11	13	0	0	0
C	11	-2.589457	-0.328200	0.867166	2	6	10	14	0	0	0
C	12	-0.074282	-0.417610	0.843859	1	5	6	22	23	0	0
H	13	-4.741983	-0.169402	0.952588	5	10	0	0	0	0	0
CL	14	-2.652363	-2.014873	0.880654	12	11	0	0	0	0	0
N	15	3.875395	-2.076249	-1.576897	8	2	16	17	0	0	0
H	16	4.790537	-1.814464	-1.865668	23	15	0	0	0	0	0
H	17	3.765859	-2.999985	-1.231375	23	15	0	0	0	0	0
CL	18	0.081402	2.600070	0.787098	12	7	0	0	0	0	0
H	19	-2.549103	3.549567	0.860617	5	8	0	0	0	0	0
H	20	-4.720430	2.323418	0.980631	5	9	0	0	0	0	0
H	21	1.716821	-2.365154	-0.164779	23	1	0	0	0	0	0
H	22	-0.233592	-1.418615	1.303861	5	12	0	0	0	0	0
H	23	0.645770	0.114447	1.506934	5	12	0	0	0	0	0
O	24	0.287656	-0.145543	-1.588990	7	5	0	0	0	0	0
H	25	2.574960	0.902200	-1.287282	23	3	0	0	0	0	0

M7 PROTONATED H33

C	1	0.472399	-1.312329	-0.349808	1	2	10	25	0	0	0
C	2	1.655398	-0.509704	0.205460	1	1	3	14	15	0	0
C	3	1.736834	0.830777	-0.529206	1	2	4	16	17	0	0
C	4	0.507661	1.652668	-0.175156	1	3	5	18	19	0	0
C	5	-0.769507	0.884443	-0.267056	2	4	6	10	0	0	0
C	6	-1.988437	1.582508	-0.292535	2	5	7	11	0	0	0
C	7	-3.215649	0.878883	-0.292147	2	6	8	12	0	0	0
C	8	-3.209618	-0.522388	-0.287849	2	7	9	20	0	0	0
C	9	-2.001959	-1.204421	-0.295160	2	8	10	21	0	0	0
C	10	-0.788507	-0.514855	-0.290461	2	1	5	9	0	0	0
O	11	-2.066460	2.953097	-0.271980	6	6	22	0	0	0	0
O	12	-4.442914	1.464161	-0.289634	6	7	23	0	0	0	0
H	13	0.656834	-1.601108	-1.407949	5	1	0	0	0	0	0
H	14	1.470959	-0.306044	1.296510	5	2	0	0	0	0	0
N	15	2.950877	-1.341963	0.125080	8	2	24	26	33	0	0
H	16	2.652188	1.392064	-0.251341	5	3	0	0	0	0	0
H	17	1.787430	0.676975	-1.627377	5	3	0	0	0	0	0
H	18	0.603915	2.048290	0.858920	5	4	0	0	0	0	0
H	19	0.452466	2.549848	-0.832441	5	4	0	0	0	0	0
H	20	-4.158286	-1.074424	-0.283202	5	8	0	0	0	0	0
H	21	-2.007977	-2.300802	-0.307235	5	9	0	0	0	0	0
H	22	-1.250596	3.286903	-0.631707	5	11	0	0	0	0	0
H	23	-4.344133	2.408349	-0.301227	5	12	0	0	0	0	0
C	24	3.211610	-2.076224	1.417848	1	15	27	28	29	0	0
H	25	0.338357	-2.258685	0.216092	5	1	0	0	0	0	0
C	26	4.154997	-0.529781	-0.277858	1	15	30	31	32	0	0
H	27	2.390718	-2.774206	1.658332	5	24	0	0	0	0	0
H	28	4.142723	-2.664935	1.360388	5	24	0	0	0	0	0
H	29	3.310842	-1.377629	2.264772	5	24	0	0	0	0	0
H	30	5.020922	-1.177158	-0.495805	5	26	0	0	0	0	0
H	31	3.943748	0.069144	-1.181229	5	26	0	0	0	0	0
H	32	4.456419	0.170573	0.519485	5	26	0	0	0	0	0
H	33	2.801719	-2.032446	-0.592406	5	15	0	0	0	0	0

MEDETOMIDINE PROTONATED H32

N	1	2.752482	-1.464196	-0.950753	9	2	5	32	0	0	0
C	2	2.716112	-1.963631	-2.233147	2	1	3	16	0	0	0
N	3	1.677558	-1.325467	-2.868110	8	2	4	17	0	0	0
C	4	1.061261	-0.429442	-1.990767	2	3	5	18	0	0	0
C	5	1.736086	-0.510908	-0.777470	2	1	4	12	0	0	0
C	6	0.134413	0.892644	0.490111	2	7	11	12	0	0	0
C	7	0.090553	2.290697	0.492602	2	6	8	19	0	0	0
C	8	-1.121307	2.964837	0.517983	2	7	9	20	0	0	0
C	9	-2.307666	2.243931	0.538268	2	8	10	21	0	0	0
C	10	-2.286757	0.848701	0.538772	2	9	11	13	0	0	0
C	11	-1.061154	0.157920	0.520876	2	6	10	14	0	0	0
C	12	1.516822	0.289608	0.466732	1	5	6	15	22	0	0
C	13	-3.585493	0.122724	0.546240	1	10	23	24	28	0	0
C	14	-1.080230	-1.330234	0.516707	1	11	29	30	31	0	0
H	15	2.250543	1.140518	0.391283	5	12	0	0	0	0	0
H	16	3.388443	-2.724126	-2.663607	5	2	0	0	0	0	0
H	17	1.408948	-1.481620	-3.807032	23	3	0	0	0	0	0
H	18	0.196766	0.202597	-2.236701	5	4	0	0	0	0	0
H	19	1.027991	2.862352	0.482992	5	7	0	0	0	0	0
H	20	-1.141076	4.060367	0.525691	5	8	0	0	0	0	0
H	21	-3.268713	2.773468	0.560219	5	9	0	0	0	0	0
C	22	1.835231	-0.471533	1.745904	1	12	25	26	27	0	0
H	23	-3.894349	-0.118064	-0.480043	5	13	0	0	0	0	0
H	24	-3.515777	-0.827983	1.099891	5	13	0	0	0	0	0
H	25	1.241528	-1.393277	1.851005	5	22	0	0	0	0	0
H	26	2.897607	-0.742656	1.816653	5	22	0	0	0	0	0
H	27	1.606715	0.155132	2.619367	5	22	0	0	0	0	0
H	28	-4.387327	0.716794	1.003334	5	13	0	0	0	0	0
H	29	-0.208386	-1.770353	1.024856	5	14	0	0	0	0	0
H	30	-1.981440	-1.719178	1.021832	5	14	0	0	0	0	0
H	31	-1.094521	-1.709497	-0.514896	5	14	0	0	0	0	0
H	32	3.395135	-1.740127	-0.248792	23	1	0	0	0	0	0

MONOXIDINE PROTONATED H29

N	1	0.978692	-0.457326	-1.606460	8	2	5	20	0	0	0
C	2	1.765794	-0.992432	-2.760292	1	1	3	15	21	0	0
C	3	2.636989	-2.087721	-2.135051	1	2	4	14	16	0	0
N	4	2.129820	-2.200966	-0.731446	9	3	5	29	0	0	0
C	5	1.210865	-1.189780	-0.463233	2	1	4	12	0	0	0
C	6	-0.544019	-0.176548	0.900774	2	7	11	12	0	0	0
C	7	-0.603557	1.230201	1.011474	2	6	8	18	0	0	0
N	8	-1.795700	1.885789	1.036633	9	7	9	0	0	0	0
C	9	-2.956415	1.181486	1.012551	2	8	10	19	0	0	0
N	10	-2.949522	-0.193735	1.020897	9	9	11	0	0	0	0
C	11	-1.785070	-0.858292	0.974547	2	6	10	13	0	0	0
N	12	0.691685	-0.913806	0.796756	8	5	6	17	0	0	0
CL	13	-1.844119	-2.541472	1.003705	12	11	0	0	0	0	0
H	14	2.523419	-3.070342	-2.633210	5	3	0	0	0	0	0
H	15	1.097260	-1.375677	-3.557242	5	2	0	0	0	0	0
H	16	3.718945	-1.842340	-2.162641	5	3	0	0	0	0	0
H	17	0.823040	-1.612987	1.493853	23	12	0	0	0	0	0
O	18	0.369454	2.172502	1.003988	6	7	22	0	0	0	0
C	19	-4.254608	1.905980	0.965849	1	9	26	27	28	0	0
H	20	0.168528	0.102948	-1.740385	23	1	0	0	0	0	0
H	21	2.357027	-0.170763	-3.211085	5	2	0	0	0	0	0
C	22	1.602087	1.894011	1.632093	1	18	23	24	25	0	0
H	23	2.263911	1.326859	0.970202	5	22	0	0	0	0	0
H	24	2.005641	2.899097	1.790476	5	22	0	0	0	0	0
H	25	1.493773	1.375058	2.591120	5	22	0	0	0	0	0
H	26	-4.598654	1.988259	-0.077242	5	19	0	0	0	0	0
H	27	-5.039764	1.380875	1.527544	5	19	0	0	0	0	0
H	28	-4.174449	2.926979	1.366253	5	19	0	0	0	0	0
H	29	2.708948	-2.585853	-0.020427	23	4	0	0	0	0	0

NORADRENALINE CRYSTAL H2O

O	1	-1.556645	3.283256	0.484788	6	7	24	0	0	0	0
O	2	-3.856775	1.852183	0.394091	6	8	22	0	0	0	0
O	3	1.049784	-2.101869	0.955452	6	11	23	0	0	0	0
N	4	3.194083	-1.439923	-0.881962	8	12	19	20	21	0	0
C	5	-0.217784	-0.131209	0.243759	2	6	10	11	0	0	0
C	6	-0.261968	1.255709	0.296082	2	5	7	13	0	0	0
C	7	-1.472195	1.955318	0.344277	2	1	6	8	0	0	0
C	8	-2.654044	1.196583	0.325635	2	2	7	9	0	0	0
C	9	-2.621796	-0.181226	0.256496	2	8	10	14	0	0	0
C	10	-1.401362	-0.849680	0.211113	2	5	9	15	0	0	0
C	11	1.133541	-0.824221	0.328497	1	3	5	12	16	0	0
C	12	1.760458	-1.042034	-1.028392	1	4	11	17	18	0	0
H	13	0.532769	1.732118	0.314919	5	6	0	0	0	0	0
H	14	-3.484478	-0.676871	0.275886	5	9	0	0	0	0	0
H	15	-1.399815	-1.763791	0.172063	5	10	0	0	0	0	0
H	16	1.768858	-0.162243	0.884294	5	11	0	0	0	0	0
H	17	1.731018	-0.213944	-1.546460	5	12	0	0	0	0	0
H	18	1.292213	-1.777873	-1.499856	5	12	0	0	0	0	0
H	19	3.585935	-1.696474	-1.679235	23	4	0	0	0	0	0
H	20	3.400854	-2.171023	-0.286771	23	4	0	0	0	0	0
H	21	3.727124	-0.745935	-0.499203	23	4	0	0	0	0	0
H	22	-3.695240	2.568895	0.401207	5	2	0	0	0	0	0
H	23	0.851628	-1.981207	1.885956	5	3	0	0	0	0	0
H	24	-1.406161	3.915458	-0.352634	21	1	0	0	0	0	0

ALPHAMETHYLNORADRENALINE PROTONATED H2O

O	1	-1.403905	3.582762	0.666299	6	7	23	0	0	0	0
O	2	-3.821305	2.152607	0.664143	6	8	21	0	0	0	0
O	3	1.047620	-1.987635	1.128556	6	11	22	0	0	0	0
N	4	2.971321	-1.438052	-0.852178	8	12	19	20	27	0	0
C	5	-0.215403	0.089208	0.659460	2	6	10	11	0	0	0
C	6	-0.173432	1.485619	0.685454	2	5	7	13	0	0	0
C	7	-1.363799	2.212949	0.694426	2	1	6	8	0	0	0
C	8	-2.611317	1.538620	0.679979	2	2	7	9	0	0	0
C	9	-2.635624	0.137190	0.672392	2	8	10	14	0	0	0
C	10	-1.443125	-0.572477	0.662477	2	5	9	15	0	0	0
C	11	1.080917	-0.672820	0.638095	1	3	5	12	16	0	0
C	12	1.639612	-0.703108	-0.831213	1	4	11	17	18	0	0
H	13	0.791934	2.006695	0.708793	5	6	0	0	0	0	0
H	14	-3.595803	-0.394530	0.676154	5	9	0	0	0	0	0
H	15	-1.473783	-1.672300	0.671105	5	10	0	0	0	0	0
H	16	1.828248	-0.166805	1.299583	5	11	0	0	0	0	0
H	17	1.804804	0.366080	-1.136219	5	12	0	0	0	0	0
C	18	0.685647	-1.351199	-1.820714	1	12	24	25	26	0	0
H	19	3.362165	-1.396298	-1.772586	23	4	0	0	0	0	0
H	20	3.601632	-1.013101	-0.200737	23	4	0	0	0	0	0
H	21	-3.701157	3.092810	0.719272	21	2	0	0	0	0	0
H	22	0.138499	-2.272985	1.189879	21	3	0	0	0	0	0
H	23	-0.590230	3.906434	1.031840	21	1	0	0	0	0	0
H	24	1.017115	-1.228139	-2.861611	5	18	0	0	0	0	0
H	25	0.534090	-2.424669	-1.631165	5	18	0	0	0	0	0
H	26	-0.306634	-0.876990	-1.741156	5	18	0	0	0	0	0
H	27	2.831914	-2.399865	-0.600330	23	4	0	0	0	0	0

UK14304 PROTONATED H28

BR	1	-1.474809	-2.634306	0.503389	13	7	0	0	0	0	0
H	2	0.549195	1.922485	0.478493	5	11	0	0	0	0	0
N	3	0.822542	-0.846236	0.499476	9	6	12	0	0	0	0
N	4	2.478748	0.464190	-0.841978	8	12	13	19	0	0	0
N	5	3.042823	-1.647929	0.200120	8	12	14	23	28	0	0
C	6	-0.360104	-0.071134	0.460344	2	3	7	11	0	0	0
C	7	-1.540915	-0.780725	0.488051	2	1	6	8	0	0	0
C	8	-2.783637	-0.130854	0.489002	2	7	9	15	0	0	0
C	9	-2.805761	1.283123	0.493522	2	8	10	20	0	0	0
C	10	-1.588199	2.014400	0.493173	2	9	11	16	0	0	0
C	11	-0.386368	1.350390	0.468438	2	2	6	10	0	0	0
C	12	1.954831	-0.632667	-0.072690	2	3	4	5	0	0	0
C	13	3.854859	0.122614	-1.299065	1	4	14	17	21	0	0
C	14	4.243020	-1.199666	-0.622024	1	5	13	18	22	0	0
N	15	-3.973642	-0.859693	0.488267	9	8	24	0	0	0	0
H	16	-1.619102	3.112758	0.515210	5	10	0	0	0	0	0
H	17	3.940864	0.057513	-2.403610	5	13	0	0	0	0	0
H	18	5.141553	-1.074791	0.020443	5	14	0	0	0	0	0
H	19	1.861496	0.796604	-1.551002	23	4	0	0	0	0	0
N	20	-4.032521	1.951199	0.494119	9	9	25	0	0	0	0
H	21	4.520261	0.954439	-0.988085	5	13	0	0	0	0	0
H	22	4.521940	-1.973359	-1.371715	5	14	0	0	0	0	0
H	23	3.274806	-1.658044	1.176311	23	5	0	0	0	0	0
C	24	-5.115277	-0.197794	0.491253	2	15	25	26	0	0	0
C	25	-5.144976	1.241075	0.491431	2	20	24	27	0	0	0
H	26	-6.038777	-0.792213	0.490654	5	24	0	0	0	0	0
H	27	-6.093127	1.795081	0.485630	5	25	0	0	0	0	0
H	28	2.750271	-2.566462	-0.077157	23	5	0	0	0	0	0

YAI1085 FROM XRAY CRYSTAL

C	1	0.224767	0.883576	0.586292	2	2	10	11	0	0	0
C	2	-1.038589	0.197247	0.664144	2	1	3	7	0	0	0
C	3	-1.100410	-1.243753	0.752024	2	2	4	18	0	0	0
C	4	-2.312623	-1.877225	0.726006	2	3	5	19	0	0	0
C	5	-3.490172	-1.108306	0.658135	2	4	6	20	0	0	0
C	6	-3.477088	0.252026	0.597159	2	5	7	21	0	0	0
C	7	-2.215840	0.939424	0.638468	2	2	6	8	0	0	0
C	8	-2.215433	2.380074	0.609443	2	7	9	22	0	0	0
C	9	-0.991798	3.017580	0.582966	2	8	10	23	0	0	0
C	10	0.189480	2.275890	0.560522	2	1	9	24	0	0	0
C	11	1.520657	0.091384	0.564776	1	1	12	17	25	0	0
C	12	1.617045	-0.709971	-0.682916	2	11	13	16	0	0	0
N	13	2.559751	-1.726810	-0.805421	9	12	14	32	0	0	0
C	14	2.434084	-2.312353	-1.983817	2	13	15	26	0	0	0
N	15	1.453109	-1.723086	-2.618448	8	14	16	31	0	0	0
C	16	0.941615	-0.710899	-1.821674	2	12	15	27	0	0	0
C	17	2.759636	0.980997	0.754219	1	11	28	29	30	0	0
H	18	-0.192743	-1.822662	0.838096	5	3	0	0	0	0	0
H	19	-2.368826	-2.955330	0.756514	5	4	0	0	0	0	0
H	20	-4.443041	-1.616666	0.654501	5	5	0	0	0	0	0
H	21	-4.399866	0.807668	0.518790	5	6	0	0	0	0	0
H	22	-3.137214	2.942853	0.608258	5	8	0	0	0	0	0
H	23	-0.952853	4.096872	0.579688	5	9	0	0	0	0	0
H	24	1.125156	2.813819	0.521218	5	10	0	0	0	0	0
H	25	1.487184	-0.577276	1.424935	5	11	0	0	0	0	0
H	26	3.032388	-3.130143	-2.357522	5	14	0	0	0	0	0
H	27	0.135326	-0.041281	-2.082269	5	16	0	0	0	0	0
H	28	3.632337	0.484555	0.329907	5	17	0	0	0	0	0
H	29	2.602859	1.934168	0.249259	5	17	0	0	0	0	0
H	30	2.922366	1.155155	1.817839	5	17	0	0	0	0	0
H	31	1.098325	-1.983118	-3.604811	23	15	0	0	0	0	0
H	32	3.284840	-1.997363	-0.052131	23	13	0	0	0	0	0